Pharmacological effects of Tirzepatide on weight loss and its adverse effects: A systematic review
DOI:
https://doi.org/10.52076/eacad-v5i3.564Keywords:
Drug therapy; Overweight; Drug-related side effects and adverse reactions; Weight loss.Abstract
The present study aims to present a literature review with analysis and description of the efficacy of Tirzepatide in weight loss and its safety profile. Tirzepatide is a synthetic molecule that acts as a dual agonist of GLP-1 and GIP receptors, hormones that regulate blood glucose and influence satiety and food intake. GLP-1 and GIP hormones play complementary roles in regulating appetite and glycemic control. GLP-1 reduces appetite, increases satiety, and improves cardiovascular function, while GIP, although with a more limited effect, also stimulates insulin secretion and improves insulin sensitivity. Tirzepatide, which combines the actions of these hormones, is administered subcutaneously once a week, with doses ranging from 5 to 15 mg. The efficacy of Tirzepatide has been evaluated in several clinical trials. The most common adverse effects include nausea, vomiting, and diarrhea, which are mild to moderate. No significant association with pancreatitis or other serious adverse events was observed. Tirzepatide did not show a significant increase in the risk of adverse cardiovascular events. It is concluded that Tirzepatide is a promising option for the treatment of obesity and type 2 diabetes, offering advantages over other therapies, with significant weight loss and an acceptable safety profile. Its ability to combine the effects of GLP-1 and GIP may provide more effective control of satiety and food intake, making it a valuable alternative in the management of these conditions.
References
ABDEL-MALEK, Mariana; YANG, Lisa; ALEXANDER DIMITRI MIRAS. Pharmacotherapy for chronic obesity management: a look into the future. Internal and Emergency Medicine, v. 18, n. 4, p. 1019–1030, 2023. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326094/>.
BAKER, Danial E.; WALLEY, Kaitlyn; LEVIEN, Terri L. Tirzepatide. Hospital Pharmacy, p. 001857872211257, 2022.
CAI, Wenting; ZHANG, Ruobin; YAO, Yao; et al. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health, v. 12, 2024. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/38356942/>.
CHAVDA, Vivek P; JINAL AJABIYA; DIVYA TELI; et al. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, v. 27, n. 13, p. 4315–4315, 2022. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/>.
DIAS, Patricia Camacho; HENRIQUES, Patrícia; ANJOS, Luiz Antonio dos; et al. Obesidade e políticas públicas: concepções e estratégias adotadas pelo governo brasileiro. Cadernos de Saúde Pública, v. 33, n. 7, 2017. Disponível em: <https://www.scielosp.org/article/csp/2017.v33n7/e00006016/pt/>.
DUTTA, Deep; SURANA, Vineet; SINGLA, Rajiv; et al. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian Journal of Endocrinology and Metabolism, v. 25, n. 6, p. 475–475, 2021. Disponível em: <https://journals.lww.com/indjem/fulltext/2021/11000/efficacy_and_safety_of_novel_twincretin.2.aspx>
FARZAM Kpatel P. Tirzepatide. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/36251836/>.
GALLWITZ, B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, v. 13, 13 out. 2022. Disponível em https://pubmed.ncbi.nlm.nih.gov/36313764/
HEISE, T. et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care, 1 mar. 2023. Disponível em: €https://pubmed.ncbi.nlm.nih.gov/36857477/
HORVATICH, Guilherme. Tizerpatida: Anvisa aprova novo medicamento promissor para o tratamento de diabetes tipo 2. Conselho Federal de Farmácia. Disponível em: <https://site.cff.org.br/noticia/Noticias-gerais/25/09/2023/tizerpatida-anvisa-aprova-novo-medicamento-promissor-para-o-tratamento-de-diabetes-tipo-2>.
LIN, F. et al. Weight loss efficiency and safety of tirzepatide: A Systematic review. PloS One, v. 18, n. 5, p. e0285197, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37141329/
MAŁECKI, M. T. et al. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4. Diabetes Care, 12 out. 2023. Disponível em:> https://pubmed.ncbi.nlm.nih.gov/37824793/
MELSON, E.; MIRAS, A. D.; & PAPAMARGARITIS, D. Future therapies for obesity. Clinical Medicine, v. 23, n. 4, p. 337–346, 1 jul. 2023. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541050/
MINISTÉRIO DA SAÚDE SECRETARIA DE CIÊNCIA, TECNOLOGIA, INOVAÇÃO E INSUMOS ESTRATÉGICOS PORTARIA SCTIE/MS No 53, DE 11 DE NOVEMBRO DE 2020. [s.l.: s.n., s.d.]. Disponível em:
MOREIRA, Rodrigo Oliveira; VALERIO, Cynthia Melissa; VILLELA-NOGUEIRA, CRISTIANE ALVES; et al. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). Arch. Endocrinol. Metab, v. 67, n. 6, 2023. Disponível em: <https://www.aem-sbem.com/wp-content/plugins/xml-to-html/include/lens/index.php?xml=2359-4292-aem-67-06-e230123.xml&lang=en>.
NAUCK, M. A.; & D’ALESSIO, D. A. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, v. 21, n. 1, p. 169, 1 set. 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36050763/
SINHA, Rachel et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. Journal of obesity & metabolic syndrome, v. 32, n. 1, p. 25, 2023.Disponível em: https://pubmed.ncbi.nlm.nih.gov/36750526/
Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clinical Diabetes, v. 40, n. 1, p. 10–38, 2022.
STEFANI, Gloria; JULIA, Anna ; & MACIEL, Mariana. Avaliação da venda de semaglutida e liraglutida em farmácias de dispensação no município de Maringá - PR. Cuadernos de Educación y Desarrollo, v. 16, n. 6, p. e4483–e4483, 2024. Disponível em: <https://cuadernoseducacion.com/ojs/index.php/ced/article/view/4483>.
Stephen J Nicholls et al. Cardiovasc Diabetol.2024. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38341541/
SATTAR, Naveed et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature medicine, v. 28, n. 3, p. 591-598, 2022.Disponível em: https://pubmed.ncbi.nlm.nih.gov/35210595/
TAVARES DE SOUZA, Marcela; DIAS DA SILVA, Michelly ; & DE CARVALHO, Rachel. Revisão integrativa: o que é e como fazer Integrative review: what is it? How to do it? Einstein, v. 8, n. 1, p. 102–108, 2010. Disponível em: <https://www.scielo.br/j/eins/a/ZQTBkVJZqcWrTT34cXLjtBx/?format=pdf&lang=pt>.
VÁRKONYI, Tamás T. et al. Perspectives on weight control in diabetes–Tirzepatide. Diabetes Research and Clinical Practice, v. 202, p. 110770, 2023.Disponível em: https://pubmed.ncbi.nlm.nih.gov/37279858/
VÁZQUEZ, Luis Alberto et al. Glycaemic control and weight reduction: a narrative review of new therapies for type 2 diabetes. Diabetes Therapy, v. 14, n. 11, p. 1771-1784, 2023.Disponível em: https://pubmed.ncbi.nlm.nih.gov/37713104/
WADDEN, Thomas A. et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine, v. 29, n. 11, p. 2909-2918, 2023.Disponível em: https://pubmed.ncbi.nlm.nih.gov/38409593/
WADDEN, Thomas A; CHAO, Ariana M; MOORE, Molly; et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports, v. 12, n. 4, p. 453–473, 2023. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/38041774/>.
WANDERLEY, Emanuela Nogueira; & FERREIRA, Vanessa Alves Obesidade: uma perspectiva plural. Ciência & Saúde Coletiva, v. 15, n. 1, p. 185–194, 2010. Disponível em: <https://www.scielo.br/j/csc/a/cxTRrw3b5DJcFTcbp6YhCry/abstract/?lang=pt>.
World Obesity Federation. World Obesity Atlas 2024. London: World Obesity Federation, 2024. https://data.worldobesity.org/publications/?cat=22
XIAOYU LV; WANG, Hui; CHEN, Chongyang; et al. The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Metabolic Syndrome and Obesity, v. 17, p. 701–714, 2024. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873148/>.
ZENG, Qingyue; XU, Jiao; MU, Xingyu; et al. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology, v. 14, 2023. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613702>.
ZWEIHARY Ali M. (2024). Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus. Cureus, 2024. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844768>.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pedro Arthur Machado da Silva; Marianna Carvalho Gomes; Fernanda da Silva Boroni; Moisés Adão Viana Guerra; Victoria Lauton Rabelo; Priscila do Valle Silva Ribeiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
